Bronchitis – Pipeline Review, 2024

Bronchitis is characterized as an inflammation of the bronchial tubes linings, known as bronchi, in the lungs. Bronchi are the medium to large-sized airways that carry air to and from the lungs. Bronchitis is mainly caused by bacteria, virus, or any other infectious particles. Based on their predominant symptoms, bronchitis can be divided into acute & chronic categories. Acute bronchitis is generally a short-term illness that follows a viral infection and cold, however, chronic bronchitis is a can occur as a result of extended illness or the environmental factors. It often generates a productive cough that lasts for over 3-4 weeks. 

The current therapy for acute bronchitis is targeted towards the alleviation of common symptoms such as cold and includes the use of antipyretics, analgesics, expectorants & antitussives. Chronic bronchitis is mostly diagnosed by pulmonary function testing. The current mainstay of chronic bronchitis management involves inhaled sympathomimetic agents such as ipratropium bromide. Antibiotics show modest improvement in the airflow, while oral steroid therapy is recommended when airflow is not achieved with the help of inhaled agents.

Currently, numerous major pharmaceutical companies are engaged in developing and studying the novel therapeutic molecules for acute & chronic bronchitis treatment. For instance; Novartis AG is conducting a trial on QBW251 for safety, tolerability, and efficacy study with QBW251 in COPD Patients. The candidate is currently being studied under phase-3.  

To know how our report can help streamline your business, Speak to Analyst

At present, over 30% of the pipeline molecules are being studied under phases 2 and around 30% of the studies are being funded by industries. Majority of the clinical studies are sponsored by pharmaceutical companies.

Report Description

The report on ‘Bronchitis – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bronchitis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bronchitis.

The report on ‘Bronchitis – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope 

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases 

Reasons to Buy this Report 

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Bronchitis
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Bronchitis
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary